Repligen | RGEN - Pre Tax Profit


Repligen reported $14.15M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Agilent USD 408M 44M Mar/2026
Align Technology USD 148.69M 193K Jun/2026
Bio Techne USD 106.09M 34.87M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Bruker USD 117M 95.1M Jun/2026
Charles River Laboratories USD -29.94M 264.16M Mar/2026
Danaher USD 1.08B 157M Jun/2026
Dentsply International USD -42M 105M Mar/2026
General Electric Aerospace USD 2.2B 654M Mar/2026
Henry Schein USD 137M 13M Jun/2026
Illumina USD 260M 103M Jun/2026
IQVIA Holdings USD 301M 5.92B Jun/2026
Mettler Toledo International USD 209.66M 119.42M Mar/2026
Myriad Genetics USD 4.6M 3.4M Dec/2025
OraSure Technologies USD -18.43M 5.14M Dec/2025
Pacific Biosciences Of California USD -40.17M 2.55M Dec/2025
Pfizer USD -653M 5.84B Jun/2026
Repligen USD 14.15M 12.38M Jun/2026
Revvity USD 187.24M 137.25M Jun/2026
Standard Biotools USD -14.62M 7.42M Mar/2026
Thermo Fisher Scientific USD 1.73B 389M Mar/2026
Waters USD 356M 444M Jun/2026
West Pharmaceutical Services USD 180.1M 18.6M Mar/2026